As of January 2022, sites in The Netherlands and the Czech Republic are continuing to enroll patients for our Phase 2 study, an optional fMRI sub-study assessing changes in brain activity in subjects with …
FOR IMMEDIATE RELEASE MDMA as an adjunct to therapy for PTSD is the forty-first treatment to receive the Innovation Passport since its inception in January 2021 The designation is intended to accelerate …
On December 10, 2021, our multi-site expanded access study site for MDMA-assisted therapy for patients with treatment-resistant PTSD at the Pearl Psychedelic Institute in Waynesville, North Carolina, was …
MAPS is sponsoring a Phase 2, open-label protocol to study the comparative effectiveness of two vs. three MDMA-assisted therapy sessions in Veterans with PTSD at the James J. Peters Veterans Affairs (VA) …
Enrollment in our food effect study on the bioavailability of MDMA in healthy volunteers is expected to begin in April 2022. This study will be conducted at a Phase 1 clinical research unit in Knoxville, …
As of January 2022, sites in The Netherlands and the Czech Republic are continuing to enroll patients for our Phase 2 study, an optional fMRI sub-study assessing changes in brain activity in subjects with …
MAPS has not received any official FDA communication on MPG1. On 13 January, the FDA informed us with a brief courtesy email that the MPG1 protocol was not yet reviewed, and they hope to review it soon. …
On December 23, 2021, the protocol for our open-label feasibility and safety study of MDMA-assisted group therapy for the treatment of posttraumatic stress disorder in Veterans (MPG1) was submitted to …
Our second Phase 3 clinical trial of MDMA-assisted therapy for PTSD is well underway, with enrollment of more than two-thirds of the participants needed to complete the study. We have also begun our long …
MAPS is sponsoring a Phase 2, open-label protocol to study the comparative effectiveness of two vs. three MDMA-assisted therapy sessions in Veterans with PTSD at the James J. Peters Veterans Affairs (VA) …
On December 8, 2021, the 30 day protocol review period passed for our open-label feasibility and safety study of MDMA-assisted group therapy for the treatment of posttraumatic stress disorder in Veterans …
MAPS is sponsoring a Phase 2, open-label protocol to study the comparative effectiveness of two vs. three MDMA-assisted therapy sessions in Veterans with PTSD at the James J. Peters Veterans Affairs (VA) …
